The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: A prospective, randomized, placebo-controlled study

Laryngoscope

Volumn 112, Issue 7 I, 2002, Pages 1221-1229

  Scott, Shaun N ^a   Boeve, Thomas J ^a   McCulloch, Timothy M ^a   Fitzpatrick, Kari A ^a   Karnell, Lucy H ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Anemia; Blood transfusion; Epoetin alfa; Erythropoietin; Head and neck cancer

Indexed keywords

FERROUS SULFATE; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FEMALE; HEAD AND NECK CANCER; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HORMONAL THERAPY; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT;

EID: 0036305011     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200207000-00015     Document Type: Article

References (63)

1. Audit of blood transfusion policy in head and neck surgery
2. A model for predicting transfusion requirements in head and neck cancer surgery
3. Transfusion, recurrence, and infection in head and neck cancer surgery
4. Blood transfusion and outcome in stage III head and neck carcinoma
5. The effect of blood transfusion upon recurrence of head and neck carcinoma: Retrospective review and meta-analysis
6. Blood transfusion and survival after laryngectomy for laryngeal carcinoma
7. Blood transfusions and recurrence in head and neck cancer
8. Blood transfusion and other prognostic variables in the survival of patients with cancer of the head and neck
9. Blood transfusion and other risk factors for recurrence of cancer of the head and neck
10. Influence of blood transfusion on recurrence, survival and postoperative infections of laryngeal cancer
11. Blood transfusion and laryngeal cancer
12. Transfusion-associated hepatitis and AIDS
13. The risk of transfusion-transmitted infection
14. Allogeneic transfusion risks in the surgical patient
15. Estimated risk of transmission of human immunodeficiency virus by screened blood in the United States
16. Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982-91
17. The risks of blood transfusion: The relative influence of acquired immunodeficiency syndrome and non-A, non-B hepatitis
18. Red cells for cancer patients
19. Autologous and heterologous blood transfusion in head and neck cancer surgery
20. Risk of wound infection in patients with head and neck cancer
21. Postoperative infections following autologous and homologous blood transfusions
22. Transfusion and host defenses against cancer recurrence and infection
23. Blood transfusion and infectious complications following colorectal cancer surgery
24. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients
25. Erythropoietin reduces anemia and transfusion: A randomized study with or without erythropoietin during chemotherapy
26. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
27. Erythropoietin for anemia in cancer patients
28. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
29. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times weekly dosing
30. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors
31. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study
32. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes
33. Multicenter study of recombinant human erythropoietin in connection of anemia in rheumatoid arthritis
34. Recombinant human erythropoietin for patients with AIDS treated with zidovudine
35. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy
36. Recombinant human erythropoietin treatment: Investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results
37. Effectiveness of perioperative human erythropoietin in elective hip replacement
38. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopedic operation
39. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients
40. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery
41. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty
42. Improving the efficacy of preoperative autologous blood donation in patients with low hematocrit: A randomized, double-blind, controlled trial of recombinant human erythropoietin
43. Epoetin alfa in low hematocrit patients to facilitate autologous blood donation in total hip replacement: A randomized, double-blind, placebo-controlled, dose-ranging study
44. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial
45. Autologous blood donation with recombinant human erythropoietin in anemic patients
46. Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anemic patients with cancer of the gastrointestinal tract
47. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: Reduced need for blood transfusions in patients undergoing colorectal surgery-prospective, double-blind, placebo-controlled study
48. Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study
49. Randomized multicenter trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anemic patients undergoing right hemicolectomy for carcinoma
50. Use of preoperative erythropoietin in head and neck cancer surgery
51. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis
52. Blood pressure and hemoglobin concentration: Multivariant analysis of local control after irradiation for head and neck cancer
53. Primary radiotherapy of larynx and pharynx carcinoma; analysis of some factors influencing local control and survival
54. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: Based on RTOG trial #7915
55. Clinical radiobiology of squamous cell carcinoma of the oropharynx
56. A multivariant analysis of the prognosis of oral squamous cell carcinomas: Are blood group and hemoglobin new prognostic factors?
57. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma
58. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx
59. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study
60. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27
61. Avoiding transfusion in head and neck surgery: Feasibility study of erythropoietin
62. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients
63. Integrated analysis of thrombotic/vascular event occurrence in epoetin alfatreated patients undergoing major, elective orthopedic surgery